CCM® Therapy

Impulse Dynamics is determined to improve the lives of people with heart failure and is the developer of the innovative Optimizer® CCM® Therapy delivery system. CCM Therapy is a breakthrough heart failure treatment proven to improve quality of life for heart failure patients. CCM Therapy is specifically designed to improve systolic contraction in an effort to deliver more oxygen-rich blood to the body. CCM Therapy is a safe and effective, minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them. Optimizer® is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM Therapy.

Our mission at Impulse Dynamics is to exceed the expectations of patients, clinicians, and caregivers alike by developing and providing cardiac contractility modulation. The company believes in fostering innovation, transparency, and accountability in our relentless efforts to expand global access to the benefits of CCM Therapy.

www.impulsedynamics.com


 

HRS 2024: CCM® Therapy for Symptomatic Heart Failure: When CRT Isn't an Option

1,999 views
June 4, 2024
This sponsored Rhythm Theatre from HRS 2024 will explain what Cardiac Contractility Modulation therapy is, how it works, and the expected outcomes when utilizing this treatment for HF in NYHA Class III patients who remain symptomatic despite guideline directed medical therapy. Dr. Jagmeet Singh discusses the challenges that continue to exist in the treatment of heart failure and the unmet needs the provider community must face together. (0 - 12:00) Dr. Sameer Jamal discussed the importance of collaboration and discussion with colleagues and shares three of his own patient experiences. (13:20 - 25:57) Dr. Niraj Varma introduces the Integra-D IDE Trial design, inclusion criteria, and current status of the trial implants. CCM-D is an investigational device in clinical trials that has both CCM® and defibrillator capabilities. (26:00 - 40:40) Dr. Rami Kahwash discusses the importance of screening patients earlier for device therapy instead of waiting until patients decompensate. The concept of introducing both device therapy and GDMT together is discussed and how to identify appropriate candidates in patients with limited options available to improve their symptoms and quality of life. (40:43 -56:09)

HRS 2024: Why Cardiac Contractility Modulation?

HRS 2024: The Impact of CCM® on My Practice

HRS 2024: Clinical Update: Future of CCM-D

HRS 2024 : Cardiac Contractility Modulation - Don’t Wait!

Comments 0
Login to view comments. Click here to Login